Celldex (CLDX) Gains after Abstract Published

September 28, 2016 8:33 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Celldex (NASDAQ: CLDX) is adding to yesterday's gain after an ESMO abstract on glembatumumab vedotin was published. Also the company is presenting at the Leerink conference on Thursday.

Shares of CLDX are up 3.6% after gaining 11.2% yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

FDA, Trader Talk

Add Your Comment